Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.00 -0.12 (-0.59%)
Streaming Delayed Price Updated: 3:10 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
34 35 Next >
News headline image
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook. 
Via Benzinga
News headline image
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death ↗
The holds are temporary while the teenager's death is under investigation. 
Via Investor's Business Daily
Topics Death
News headline image
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings) ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen... 
Via StockStory
Topics Artificial Intelligence
News headline image
This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price... 
Via StockStory
News headline image
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
News headline image
Is This Stock a Buy After a Massive 20% Drop in 1 Day? ↗
Via The Motley Fool
News headline image
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up ↗
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case. 
Via Stocktwits
News headline image
Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31 
Via Benzinga
Topics Economy Stocks
News headline image
12 Analysts Have This To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday? ↗
Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York. 
Via Benzinga
News headline image
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with... 
Via StockStory
News headline image
Discover the top movers in Tuesday's pre-market session. ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges ↗
Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor. 
Via Benzinga
News headline image
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies ↗
The patient also had a recent CMV infection, which the company said could have contributed. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases ↗
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
News headline image
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations ↗
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.